Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum ® technology, today announced the opening of a new office at McMaster Innovation Park in Hamilton, Ontario, supporting the Company's expanding radiopharmaceutical research and business development activities. Hamilton has emerged as one of Canada's leading hubs for radiopharmaceutical innovation, bringing together world-class capabilities spanning isotope production, radiopharmaceutical discovery, translational research, GMP manufacturing, and clinical translation. Anchored by McMaster University, alongside internationally recognized institutions and a rapidly expanding ecosystem of radiopharmaceutical companies, the region is positioning Hamilton at the forefront of next-generation precision medicine, while helping establish Canada as a global leader in the field. "Our expansion into McMaster Innovation Park reflects both the growth of our company and the increasing momentum of our radiopharmaceutical programs," said Sébastien Plouffe, Chief Executive Officer of Defence Therapeutics. "As we continue to advance the Accum ® platform, this strategic positioning allows us to build new collaborations, access exceptional expertise and further strengthen the foundation we are building to develop the next generation of precision oncology therapies." McMaster Innovation Park has become home to a growing community of life sciences innovators, offering specialized infrastructure and a collaborative environment designed to accelerate scientific innovation and commercialization. "We are pleased to welcome Defence Therapeutics to McMaster Innovation Park. Companies like Defence strengthen the collaborative innovation ecosystem that helps scale companies and advance emerging strengths i...